Categories: Technology

Quadient Announces Supplier Agreement with Vizient, Enhancing Access to the U.S. Healthcare Market

Quadient Announces Supplier Agreement with Vizient, Enhancing Access to the U.S. Healthcare Market

Quadient (Euronext Paris: QDT), a global automation platform powering secure and sustainable business connections, has entered into a supplier agreement with Vizient, the largest provider-driven healthcare performance improvement company in the U.S. Vizient’s diverse client base includes some of the country’s most prestigious hospitals and integrated health delivery networks. The agreement enhances opportunities for Quadient to serve healthcare providers across the continuum of care, offering contracted pricing for a wide range of the company’s digital software, mail and automated locker solutions.

Vizient provides network-powered insights into the critical areas of clinical, operational and spend management performance and empowers clients to deliver exceptional, cost-effective care. Serving more than 65% of U.S. acute care providers and more than 35% of the non-acute market, Vizient’s contract portfolio represents $140 billion in annual purchasing volume. Through the new contract, healthcare providers have greater access to Quadient’s cutting-edge solutions designed to enhance digital patient interactions, optimize the sending and receiving of mail and packages, improve operational efficiency, increase document security and ensure regulatory compliance.

“We are thrilled to be awarded a contract from Vizient to help healthcare organizations improve performance through more streamlined and automated workflows, leading to better patient and staff experiences” said Geoffrey Godet, CEO at Quadient. Our strategic approach to supply chain and procurement in the mailing and communications space is rooted in a comprehensive, assessment-based process that identifies key assets and opportunities to drive efficiency and transformation for healthcare providers. We are excited to support Vizient clients with innovative, results-driven solutions that enhance operational performance and elevate the overall healthcare experience.”

For more information about Quadient’s solutions and contract with Vizient, visit www.quadient.com and mail.quadient.com/en/healthcare-contracts/Vizient.

About Quadient®
Quadient is a global automation platform powering secure and sustainable business connections through digital and physical channels. Quadient supports businesses of all sizes in their digital transformation and growth journey, unlocking operational efficiency and creating meaningful customer experiences. Listed in compartment B of Euronext Paris (QDT) and part of the CAC® Mid & Small and EnterNext® Tech 40 indices, Quadient shares are eligible for PEA-PME investing. For more information about Quadient, visit http://www.quadient.com/en/.

Media Contacts
Joe Scolaro, Quadient
Global Press Relations Manager
+1 203-301-3673
jscolaro@quadient.com

Kiley Ribordy, Walker Sands
Senior PR Director
quadientpr@walkersands.com

GlobeNews Wire

Recent Posts

FemiCore (Official Website & Authenticity Notice 2026) Counterfeit Risks and What Consumers Should Know

New York City, NY, June 13, 2026 (GLOBE NEWSWIRE) -- The women's health supplement market…

11 hours ago

Hitch Open Ping-Pong Embodied (HOPE) AI Challenge Joins the 2026 World Humanoid Robot Games, Seeding Advanced Physical AI Against Human Performance

BEIJING, June 13, 2026 (GLOBE NEWSWIRE) -- The 2026 Hitch Open Ping-Pong Embodied AI Challenge…

11 hours ago

Crypto News Today: AlphaPepe Unveils AlphaSwap Early Access as Bitcoin Price Prediction Eyes $250,000

MONACO, June 12, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe after…

11 hours ago

Hexaware Expands Presence in Gujarat with New Delivery Center at GIFT City

MUMBAI, India, LONDON and ISELIN, N.J., June 13, 2026 /PRNewswire/ -- Hexaware Technologies [NSE: HEXT], a…

13 hours ago

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI…

14 hours ago

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

June 13, 2026 07:30 ET  | Source: Intellia Therapeutics, Inc. Data from HAELO Phase 3…

14 hours ago